NF-κB/IκB

Shop By

Items 51-100 of 168

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. IκB/IKK Inhibitor

    SC-514 is an orally active, ATP-competitive IKKβ inhibitor (IC50 = 3 - 12 μM) that displays > 10-fold selectivity over 28 other kinases including JNK, p38, MK2 and ERK.
  2. NF-κB inhibitor

    QNZ inhibits the activation of the transcription factor NF-κB and has been used to investigate NF-κB signaling.
  3. HDAC6 inhibitor

    ACY-241 is a new, selective and orally available inhibitor of HDAC6.
  4. IKK inhibitor

    PS-1145 is a highly specific IKB kinase (IKK) inhibitor that efficiently inhibits both basal and induced NF-kB activity in PC cells.
  5. IKK Inhibitor

    IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.
  6. IKK Inhibitor

    IMD 0354 is an inhibitor of IκB kinase-β (IKKβ) that blocks NF-κB nuclear translocation.
  7. HDAC6 inhibitor

    BRD9757 is a highly potent and selective HDAC6 inhibitor with an IC50 of 30 nM toward HDAC6.
  8. EBP1 Inhibitor

    WS3 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
  9. EBP1 Inhibitor

    WS6 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
  10. IKK-2 inhibitor

    PHA 408 is a potent, highly selective and ATP-competitive IKB kinase-2 (IKK-2) inhibitor (IC50: 40 nM), which binds IKK-2 tightly with a relatively slow off rate; highly recommended tool to investigate the mechanisms by which IKK-2 regulates NF-KB signaling.
  11. HDAC inhibitor

    RG2833 ( is a brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3.
  12. HDAC3 inhibitor

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM, exhibits > 200-fold selectivity over other HDAC.
  13. JAK2/HDAC dual inhibitor

    JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines.
  14. HDACs/mTOR Inhibitor 1

    HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies.
  15. IKKβ inhibitor

    BI605906 is a novel inhibitors of the IKK beta.
  16. NF-κB activation inhibitor

    Caffeic acid phenethyl ester is a potent and specific inhibitor of NF-κB activation
  17. HDAC6 inhibitor

    Nexturastat A is an aryl urea derivative that acts as a potent and highly selective inhibitor of histone deacetylase 6 (HDAC6) (IC50= 5.02 +/- 0.60 nM).
  18. HDAC inhibitor

    TMP 269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
  19. NF-κB inhibitor

    JSH 23 is an inhibitor of NF-kB, blocking its translocation into the nucleus (IC50 = 7.1 uM)
  20. HDAC6 inhibitor

    HPOB is a potent inhibitor of histone deacetylase 6 (HDAC6; IC50 = 56 nM).
  21. NAD(+)-dependent histone deacetylase Sir2p inhibitor

    Splitomicin is a selective NAD(+)-dependent histone deacetylase Sir2p inhibitor with IC50 of 60 uM, showing a higher activity in a cell-based assay.
  22. HDAC inhibitor

    Santacruzamate A (CAY10683) is a potent and selective HDAC inhibitor with IC50 of 119 pM for HDAC2, >3600-fold selectivity over other HDACs.
  23. NF-κB inhibitor

    SC75741 is a potent NF-kB inhibitor with EC50 of 200 nM.
  24. HDAC inhibitor

    TMP195 is the most potent and selective class IIa HDAC inhibitor.
  25. HDAC4/5 inhibitor

    LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor.
  26. HDAC inhibitor

    4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.
  27. HDAC inhibitor

    ST7612AA1 is a new and potent HDAC inhibitor with potential anticancer activity.
  28. IKK Inhibitor II

    Wedelolactone, a compound originally extracted from Eclipta alba, has been shown to inhibit caspase-11, which is a key regulator of proinflammatory cytokine IL-1β maturation and pathological apoptosis.
  29. IKK Inhibitor?€?

    Bay 65-1942 (R form) is an ATP-competitive inhibitor that selectively targets IKKβ kinase.
  30. NF-κB inhibitor

    CID-2858522 selectively inhibits the NF-κB pathway (IC50 < 0.1 uM for PMA-stimulated IL-8 production) induced by PKC, operating downstream of PKC but upstream of IKKbeta, without inhibiting other NF-kappaB activation pathways.
  31. IκB Kinase β Inhibitor

    MLN120B is a potent and effective IKKbeta inhibitor.
  32. HDAC inhibitor

    Resminostat hydrochloride is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM.
  33. HDAC inhibitor

    KD 5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
  34. HDAC Inhibitor

    NCH 51 is a cell-permeable prodrug that is intracellularly converted to a potent HDAC inhibitor, with an IC50 of 48 nM.
  35. HDAC Inhibitor

    NSC 3852 is an HDAC (histone deacetylase) inhibitor.
  36. HDAC inhibitor

    TC-H 106 is a slow, tight-binding inhibitor of class I HDACs (histone deacetylases).
  37. HDAC6 inhibitor

    TCS HDAC6 20b, selective inhibitor of histone deacetylase 6 (HDAC6). Inhibits HCT116 growth in combination with taxol. Also inhibits growth of MCF-7 cells stimulated by estrogen.
  38. HDAC inhibitor

    R306465 is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and haematological malignancies in preclinical models.
  39. IKK2 inhibitor

    LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.
  40. HDAC inhibitor

    BRD73954 is a small molecule inhibitor that potently inhibits both HDAC6 and HDAC8 (IC50s = 36 and 120 nM, respectively).
  41. HDAC/ACE inhibitor

    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM, and also inhibits ACE-I activity. Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells.
  42. HDAC inhibitor

    UF010 is a potent and selective HDAC inhibitor with IC50 ~0.06 uM, 0.1 uM, 0.5 uM and 1.5 uM for HDACs 3, 2, 1 and 8, respectively. It has > 6-fold selectivity over other HDACs.

  43. IKK2 inhibitor?€?

    AZD3264 is a novel IKK2 inhibitor.
  44. HDAC6 inhibitor

    ACY-738 is a potent and selective HDAC6 inhibitor with improved brain bioavailability. ACY-738 inhibits HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs.
  45. HDAC inhibitor

    BML-210 is HDAC inhibitor. BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.
  46. HDAC inhibitor

    ITSA-1 is membrane permeable and specifically suppresses TSA inhibition of HDAC (histone deacetylase), but not other HDAC inhibitors.
  47. ERK/Akt/NF-kB inhibitor

    Tomatidine inhibits the phosphorylation of ERK, Akt, and the nuclear content of NF-kB. possess anti-inflammatory properties.
  48. IKKε /TBK1 inhibitor

    Amlexanox is an anti-inflammatory antiallergic immunomodulator used to treat recurrent aphthous ulcers (canker sores), and (in Japan) several inflammatory conditions.
  49. IKK-ε inhibitor

    IKK epsilon-IN-1 is a potent IKKε inhibitor; inhibit the in-situ IKK ε-mediated phosphorylation of IRF3 with an IC50 value of less than about 100 nM.

Items 51-100 of 168

per page
Set Descending Direction